Qiagen (NYSE:QGEN) Price Target Lowered to $55.00 at Citigroup

Qiagen (NYSE:QGEN) had its price target lowered by Citigroup from $55.40 to $55.00 in a report published on Friday,Benzinga reports. The firm currently has a neutral rating on the stock.

QGEN has been the topic of a number of other research reports. Wall Street Zen downgraded Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Deutsche Bank Aktiengesellschaft lowered Qiagen from a “buy” rating to a “hold” rating and upped their price objective for the stock from $52.00 to $54.00 in a research report on Thursday, January 22nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $59.00 target price on shares of Qiagen in a report on Thursday. TD Cowen reiterated a “hold” rating on shares of Qiagen in a research note on Friday. Finally, Stifel Nicolaus set a $50.00 price target on shares of Qiagen and gave the stock a “hold” rating in a report on Friday. Four equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, Qiagen currently has an average rating of “Hold” and an average target price of $55.27.

Qiagen Stock Down 0.3%

QGEN stock opened at $51.08 on Friday. The firm’s fifty day simple moving average is $49.65 and its 200-day simple moving average is $49.67. The company has a market capitalization of $10.79 billion, a P/E ratio of 25.33, a price-to-earnings-growth ratio of 2.57 and a beta of 0.67. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30. Qiagen has a 12 month low of $39.61 and a 12 month high of $57.81.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.01. Qiagen had a net margin of 20.33% and a return on equity of 14.82%. The firm had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. During the same quarter last year, the company posted $0.61 earnings per share. The firm’s revenue was up 3.6% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. As a group, equities research analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Institutional Investors Weigh In On Qiagen

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Danske Bank A S purchased a new position in Qiagen during the third quarter valued at $36,000. Smartleaf Asset Management LLC raised its position in shares of Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after purchasing an additional 830 shares during the last quarter. MAI Capital Management lifted its stake in Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after buying an additional 889 shares in the last quarter. Global Retirement Partners LLC boosted its holdings in Qiagen by 279.9% in the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after buying an additional 851 shares during the last quarter. Finally, Allworth Financial LP boosted its holdings in Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after buying an additional 796 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Trending Headlines about Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: JPMorgan raised its price target to $60 and set an “overweight” rating, signaling ~17.5% upside from current levels. This analyst upgrade is a near-term bullish catalyst. Article Title
• Positive Sentiment: Unusually large options activity: traders bought ~40,639 call options (a ~4,600% increase vs. average), suggesting some investors are positioning for upside. (no article link provided)
• Positive Sentiment: Management reiterated a sales-growth target (at least ~5% sales growth for 2026), which supports topline momentum assumptions even as profitability is pressured. Article Title
• Neutral Sentiment: Citigroup trimmed its target slightly to $55 and moved to “neutral” — a modest calibration rather than a stark downgrade; this tempers but does not reverse bullish signals. Article Title Ticker Report
• Neutral Sentiment: Q4 results: EPS roughly in line ($0.62, vs. $0.61 consensus) and revenue modestly beat — evidence of steady demand but not a breakout. Zacks Earnings Article
• Neutral Sentiment: Full earnings materials and call transcript are available for deeper read‑throughs (slides, call transcript) — useful for investors assessing guidance drivers and margin details. Press Release Earnings Transcript
• Negative Sentiment: Guidance disappointed: Q1 EPS guidance (~$0.54) and FY‑2026 EPS (≈$2.50) were below Street consensus, which pressured sentiment as investors focus on margin recovery and near‑term profitability. Press Release
• Negative Sentiment: Margin contraction noted in coverage: analysts and news pieces flagged margin pressure and cautious tone on 2026, which was a primary reason the stock sold off despite the top‑line beat. Zacks Margin Article

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.